Amyloid-beta (Aβ) accumulating neurons are neuronal populations that selectively accumulate toxic Aβ oligomers and aggregates, representing key cellular substrates of Alzheimer's disease pathophysiology. Understanding which neurons preferentially accumulate Aβ, the mechanisms driving this selectivity, and the consequences for neuronal function provides insights into AD progression and therapeutic targeting.[1]
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000169 | type B pancreatic cell |
Neuronal vulnerability to Aβ accumulation depends on multiple factors:[2]
| Factor | Mechanism | Vulnerable Populations |
|---|---|---|
| High metabolic activity | ↑ ROS, ↑ APP processing | Layer III/V pyramidal |
| Long axons | ↑ axonal transport demand | Corticospinal neurons |
| Low Ca2+ buffering | ↑ Ca2+ toxicity | Dopaminergic neurons |
| Large soma size | ↑ protein synthesis | Betz cells |
| Specific molecular profile | ↑ BACE1, ↓ neprilysin | Entorhinal cortex |
Aβ accumulation follows a stereotyped regional pattern (Braak staging):[3]
Stage I-II (Transentorhinal):
Stage III-IV (Limbic):
Stage V-VI (Neocortical):
Entorhinal stellate cells are among the first affected:[4]
CA1 pyramidal neurons accumulate Aβ with progression:[5]
Cortical pyramidal neurons in layers III and V show Aβ vulnerability:[6]
| Layer | Neuron Type | Aβ Mechanism |
|---|---|---|
| III | Intratelencephalic | Corticocortical disconnect |
| V | Pyramidal tract | Motor/executive dysfunction |
| V | Callosal projection | Interhemispheric impairment |
Locus coeruleus neurons show early Aβ pathology:[7]
Aβ oligomers disrupt synaptic function through:[8]
Receptor Internalization:
Spine Loss:
Plasticity Impairment:
Aβ causes calcium dysregulation via:[9]
Aβ targets mitochondrial function:[10]
Aβ overwhelms protein quality control:[11]
| System | Aβ Effect | Consequence |
|---|---|---|
| Ubiquitin-proteasome | Proteasome inhibition | Protein aggregation |
| Autophagy | Impaired flux | LC3 accumulation |
| ERAD | Overwhelmed | ER stress |
| Chaperones | Sequestered by Aβ | Loss of function |
Aβ accumulation triggers inflammatory responses:[12]
Aβ generates oxidative damage:[13]
Neurons attempt to compensate for Aβ:[14]
Certain neurons show relative resistance:[15]
| Factor | Protective Mechanism |
|---|---|
| High Ca2+ buffering (calbindin) | Reduced Ca2+ toxicity |
| Efficient Aβ clearance | ↑ LRP1, neprilysin |
| Robust antioxidant systems | ↑ glutathione, SOD |
| Strong proteostasis | ↑ proteasome activity |
| Low metabolic demand | ↓ ROS production |
Calbindin-positive neurons resist Aβ toxicity:[16]
Enhancing neuronal Aβ clearance:[17]
Enzyme Enhancement:
Receptor-Mediated Clearance:
Immunotherapy:
Protecting vulnerable neurons:[18]
| Marker | Type | Expression | Significance |
|---|---|---|---|
| 6E10 | Antibody | Aβ1-16 | Plaque detection |
| 4G8 | Antibody | Aβ17-24 | Total Aβ |
| Aβ42 | Peptide | Intracellular | Toxic species |
| APP | Protein | Membrane | Aβ precursor |
| BACE1 | Enzyme | Endosomes | Aβ production |
| Neprilysin | Enzyme | Membrane | Aβ degradation |
Plasma Aβ42/40: FDA-approved (PrecivityAD)
Aβ PET concordance: High accuracy
Population screening potential
Alzheimer's disease
Locus Coeruleus
Corticospinal neurons
Hippocampal CA1
Entorhinal stellate cells
CA1 pyramidal neurons
Locus coeruleus
Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016. ↩︎
Jebara L, et al. Neuronal vulnerability in Alzheimer's disease: from genes to pathology. Front Neurosci. 2023. ↩︎
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991. ↩︎
Khan UA, et al. Molecular drivers and cortical layer II–III neurons of the entorhinal cortex affected in Alzheimer's disease. Nat Neurosci. 2014. ↩︎
Simone L, et al. Vulnerability of CA1 synapses to Aβ: the role of mitochondrial dysfunction. J Alzheimers Dis. 2020. ↩︎
de Frutos Lucas J, et al. Selective vulnerability of cortical neuron types in Alzheimer's disease. Front Cell Neurosci. 2023. ↩︎
Braak H, Del Tredici K. Vulnerability of select neuronal types to Alzheimer's disease. Ann N Y Acad Sci. 2010. ↩︎
Shankar GM, et al. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008. ↩︎
Demuro A, et al. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem. 2005. ↩︎
Manczak M, et al. Mitochondria are a direct site of Aβ accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet. 2006. ↩︎
Tseng BP, et al. Amyloid-β accumulation impairs the ubiquitin-proteasome system. J Neurochem. 2008. ↩︎
Heneka MT, et al. [Neuroinflammation in Alzheimer's disease](https://doi.org/10.1016/S1474-4422(15). Lancet Neurol. 2015. ↩︎
Butterfield DA, et al. Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med. 2007. ↩︎
Zheng H, Koo EH. Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegener. 2011. ↩︎
Bussière T, et al. Morphological basis of neuronal vulnerability in Alzheimer's disease. Acta Neuropathol. 2021. ↩︎
Palop JJ, Mucke L. Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci. 2010. ↩︎
Seubert P, et al. Amyloid-clearing strategies in Alzheimer's disease. J Neurochem. 2022. ↩︎
Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019. ↩︎